TCRX advances solid-tumor TCR programs to IND-enabling stage
TCRX said two in vivo solid-tumor TCR therapies (PRAME, MAGE-A4) moved to IND-enabling stage with clinical trials planned for late 2027. Heme and autoimmune efforts are paused; financial runway extended into Q4 2027.